CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

202356Orig1s000

MICROBIOLOGY / VIROLOGY REVIEW(S)

Product Quality Microbiology Review

01 October 2013

NDA: **50-629/S-024 (Lead Supplement)**

Drug Product Name **Bundled Supplement**

	Proprietary	Non-Proprietary
NDA 50-629/S-024	Doxorubicin HCl Injection, USP	Doxorubicin HCl Injection, USP
NDA 50-778/S-020	Ellence®	Epirubicin HCl injection
NDA 50-734/S-021	Idamycin PFS®	Idarubicin HCl injection
NDA 202-356/N000	Docetaxel Injection Concentrate (10 mg/mL)	Docetaxel Injection Concentrate (10 mg/mL)

Review Number: **1**

Subject of this Review

	Submit Date	Received Date	Review Request	Assigned to Reviewer
NDA 50-629/S-024	06/21/2013	06/21/2013	08/08/2013	08/08/2013
	09/17/2013	09/17/2013	n/a	n/a
NDA 50-778/S-020	06/21/2013	06/21/2013	08/08/2013	08/08/2013
	09/17/2013	09/17/2013	n/a	n/a
NDA 50-734/S-021	06/21/2013	06/21/2013	08/08/2013	08/08/2013
NDA 202-356/N000	06/28/2013	06/28/2013	08/08/2013	08/08/2013

Submission History (for amendments only): N/A

Applicant/Sponsor

Name: Pfizer, Inc., (Agent for Pharmacia and Upjohn Company)

Address: 235 East 42nd Street
New York, NY 10017

Representative: Tricia Racanelli, Director, Worldwide Regulatory Strategy

Telephone: 212-733-2530

Name of Reviewer: Robert J. Mello, Ph.D.

Conclusion: Recommended for approval

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Prior Approval Supplement

2. SUBMISSION PROVIDES FOR: Comparability protocol for proposed changes to the aseptic oncology manufacturing facility at Pfizer (Perth) Pty Limited, Australia

- Replacement of [redacted] (b) (4) [redacted] (b) (4)
- Manufacturing facility modifications to accommodate the new [redacted] (b) (4) and improve [redacted] (b) (4)
- Improve [redacted] (b) (4) within support areas

3. MANUFACTURING SITE: Pfizer (Perth) Pty Limited
ABN 32 051 824 956
15 Brodie Hall Drive
Bentley WA 6102
Australia

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: Injection, Intravenous infusion, Various potencies

5. METHOD(S) OF STERILIZATION: [redacted] (b) (4)

6. PHARMACOLOGICAL CATEGORY: Cancer chemotherapeutic

B. SUPPORTING/RELATED DOCUMENTS: None

C. REMARKS:

- The submission is in eCTD format located in EDR.
- This is a bundled supplement consisting of 3 approved NDAs and 1 NDA that is currently under review.
- An information request was transmitted to the Applicant on 10 September 2013. The Applicant responded on 17 December 2013. Their response is incorporated into the text of the review (see page 9).

filename: N050629S024R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability - Recommended for Approval

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable - N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology - The listed products are sterilized by [redacted] (b) (4).
The proposed facility renovations impact sterile component preparation, product and process flow in and around the aseptic area and environmental controls within a proposed expansion of the process support areas of the facility.

B. Brief Description of Microbiology Deficiencies - None

C. Assessment of Risk Due to Microbiology Deficiencies – N/A

D. Contains Potential Precedent Decision(s)- ☐ **Yes** ☒ **No**

III. Administrative

A. Reviewer's Signature _____
Robert J. Mello, Ph.D.
Senior Microbiology Reviewer

B. Endorsement Block _____
John W. Metcalfe, Ph.D.
Senior Microbiology Reviewer

C. CC Block
NDA 50-629/S-024
NDA 50-778/S-020
NDA 50-734/S-021
NDA 202-356/N000

10 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT J MELLO
10/01/2013

JOHN W METCALFE
10/01/2013
I concur.

Product Quality Microbiology Review

25-JAN-2012

NDA 202-356/N-000

Drug Product Name
Proprietary: None
Non-proprietary: Docetaxel Injection Concentrate (DIC)

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
29-APR-2011	29-APR-2011	20-MAY-2011	20-MAY-2011

Applicant/Sponsor
Name: Pfizer, Inc.
Address: 235 East 42nd Street
New York, NY 10017
Representative: Beatrice Curran
Associate DICrector
Worldwide Regulatory Strategy
Telephone: 212-733-2061

Name of Reviewer: Steven Fong, Ph.D.

Conclusion: CMC-Microbiology Recommends APPROVE.

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original NDA.

2. SUBMISSION PROVIDES FOR: New drug product.

3. MANUFACTURING SITE:
Pfizer (Perth) Pty Limited
15 BroDICe Hall drive
Bentley WA 6102
Australia

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:
- Solution injection for intravenous infusion.
- Provided in 4 X 10 mg/mL presentations:
  - 20 mg in 2 mL
  - 80 mg in 8 mL
  - 130 mg in 13 mL
  - 200 mg in 20 mL

5. METHOD(S) OF STERILIZATION: (b) (4)

6. PHARMACOLOGICAL CATEGORY: Cancer therapeutic.

B. SUPPORTING/RELATED DOCUMENTS:

1) DMF 16319, the holder for which is Pfizer (Perth) Pty Ltd, describing manufacture of DIC drug product, and a LOA from Pfizer dated 09-FEB-2011 authorizing Agency review of the File.

2) A microbiology quality review of DMF 16319 dated 25-JAN-2012 that deemed the File adequate in support of the referenced NDA.

2) DMF (b) (4), the holder for which is (b) (4), describing (b) (4), and a LOA from (b) (4) dated 05-OCT-2010 authorizing Agency review of the File.

3) A microbiology quality review of DMF (b) (4) dated 25-JAN-2012 that deemed the File adequate in support of the referenced NDA.

C. REMARKS:
- The subject NDA was submitted electronically in CTD format under the Section 505(b)(2) regulatory pathway. The drug product represents a reformulation of the innovator drug, Taxotere 40 mg/mL. The latter is

manufactured by Sanofi-Aventis and was approved 14-MAY-1996 under NDA 20-449/N-000.

filename: N202356r1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability – Recommended for approval from a microbiology quality standpoint.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – (b) (4)

(b) (4)

B. Brief Description of Microbiology Deficiencies - None

C. Assessment of Risk Due to Microbiology Deficiencies – N/A

III. Administrative

A. Reviewer's Signature _____

Steven E. Fong, Ph.D.
Microbiology Reviewer

B. Endorsement Block _____

John W. Metcalfe, Ph.D.
Senior Microbiology Reviewer

C. CC Block—N/A

11 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEVEN E FONG
01/25/2012
Recommended for approval from a microbiology quality standpoint.

JOHN W METCALFE
01/25/2012
I concur.

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 202-356/N-000 **Applicant: Pfizer, Inc.** **Submit Date: 29-APR-2011**

Drug Name: Docetaxel Injection Concentrate 10 mg/mL **NDA Type: Original NDA** **Receipt Date: 29-APR-2011**

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		Submission provided electronically in CTD format.
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		Sections 2.3.P and 3.2.P.3.3
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	X		Section 3.2.P.3.5
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	Submission was provided in English.
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	X		Product is not preserved. Container closure integrity described in section 3.2.P.2.7
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		Sections 2.3.P.5.1 and 3.2.P.5.1.
7	Has the applicant submitted the results of analytical method verification studies?	X		Sections 2.3.P.5.1.4, 2.3.P.5.1.5, 3.2.P.5.2, and 3.2.P.5.3.
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	N/A	N/A	Pre-submission microbiology quality requests were not made.
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments: The drug product, Docetaxel Injection 10 mg/mL, is provided in four presentations containing 20 mg/2 mL, 80 mg/8 mL, 130 mg/13 mL, and 200 mg/20 mL docetaxel (anhydrous) drug substance. The product is manufactured using (b) (4)

Steven Fong, Ph.D. 03-JUN-2011
Review Microbiologist

John Metcalfe, Ph.D. 03-JUN-2011
Senior Review Microbiologist

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEVEN E FONG
06/03/2011

JOHN W METCALFE
06/03/2011
I concur.